Filing summary
Entity mismatch: The supplied filing is Anzu Special Acquisition Corp I’s Form 10-Q, not a filing identified as Envoy Medical, Inc. It covers the quarter ended June 30, 2022. Anzu describes itself as a blank-check company seeking a business combination, with a stated focus on industrial transformative technologies. It had no operating revenue or business operations.
Financial performance and position
| Metric | Q2 2022 / June 30, 2022 | Comparable period / prior year-end |
|---|---|---|
| Operating revenue | None | None |
| Operating costs | $901,356 for the quarter; $2,390,442 for six months | Quarter: $1,071,142; six months: $1,254,607 in 2021 |
| Net income (loss) | $3,090,719 for the quarter; $15,552,100 for six months | Quarter: $371,144; six months: $(1,099,292) in 2021 |
| Cash and cash flow | $476,948 cash outside the trust; six-month operating cash use of $1,172,897 | $149,845 cash at December 31, 2021; operating cash use of $1,654,299 in first-half 2021 |
| Trust investments | $425,641,451 | $425,037,665 at December 31, 2021 |
| Working capital and debt | Working-capital deficit of $4,313,763; $1,500,000 related-party working-capital loan outstanding | Working-capital deficit of $1,815,006 at December 31, 2021; no loan balance then |
| Warrant liabilities | $3,200,000 | $21,063,972 at December 31, 2021 |
Reported earnings were substantially affected by noncash fair-value changes: the six-month net income included a $17,863,972 gain from lower warrant-liability value, while the forward purchase agreement generated a $416,901 loss. Interest income on trust assets was $603,786 for the six months. Operating cash use, rather than reported net income, is more indicative of the company’s cash needs. Profit margins are not applicable because the company had no operating revenue.
Changes, liquidity and transaction arrangements
- Six-month results improved from a net loss in 2021 to net income in 2022, chiefly because of the warrant-liability fair-value gain and higher trust interest income; operating expenses increased year over year.
- Cash outside the trust increased from year-end, supported by $1.5 million in sponsor working-capital loans. The company reported a substantial working-capital deficit and said it may need additional financing. The sponsor is not obligated to provide further funds beyond the stated loan facility.
- The company had until March 4, 2023, or an approved extension, to complete a business combination; otherwise, it would be required to wind up and redeem public shares under the stated terms. Management disclosed substantial doubt about the company’s ability to continue as a going concern if it did not complete a combination.
- Forward purchase agreements contemplated up to $80 million of convertible notes and up to $40 million of forward-purchase securities, subject to conditions and negotiated terms. The filing says no notes were outstanding and no action had been taken on the securities beyond the agreements.
Risks, contingencies and subsequent events
- The $14,875,000 deferred underwriting fee is payable from trust assets only if a business combination closes. The public warrants may expire worthless if no combination is completed.
- Management cited COVID-19 and the Russia-Ukraine conflict as uncertainties whose effects were not determinable. It also warned that proposed SEC SPAC rules could increase transaction costs and affect the ability to complete a combination.
- After quarter-end, the CFO, general counsel/corporate secretary, and two directors announced resignations, effective around July 31 or after the report filing, as applicable.
- Management said disclosure controls were effective and the previously reported material weakness in controls over complex financial instruments had been remediated. No material legal proceedings were reported.
- The cover page marks “No” for having filed all required Exchange Act reports during the preceding 12 months; the reason and any implications are not clear from the supplied text.
Key facts for investors to verify
- Confirm the intended issuer: this filing is for Anzu Special Acquisition Corp I, not Envoy Medical, Inc.
- Verify the status of any business-combination search or proposed transaction, any extension to the March 4, 2023 deadline, and subsequent financing.
- Assess liquidity outside the trust, the working-capital loan’s repayment or conversion terms, and the going-concern disclosure.
- Confirm the significance of the cover-page indication that the company had not filed all required reports, and review the post-quarter leadership departures.
- Reconcile the administrative-services fee: the notes state $40,521 per month, while MD&A states $40,251.